← Back to Search

Brain Stimulation

rTMS for Cannabis Use Disorder

N/A
Recruiting
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms)
Awards & highlights

Study Summary

This trial will explore brain-based approach (rTMS) to treat cannabis use disorder (CUD), to reduce craving and consumption and improve executive function. It could provide the first widely adopted clinical rTMS intervention for CUD.

Who is the study for?
This trial is for adults aged 18-65 with cannabis use disorder, using cannabis at least 5 days a week and aiming to reduce or quit. They must have a certain level of dependency and be on stable psychiatric meds if any. Excluded are pregnant individuals, those with severe mental health disorders, other primary substance abuse issues, seizure history, significant head injury, unstable medical conditions, or specific medications.Check my eligibility
What is being tested?
The study tests repetitive transcranial magnetic stimulation (rTMS) using the MMC-140 coil on people with cannabis use disorder over four weeks. It will assess how well this non-invasive brain stimulation works in reducing cravings and consumption by exciting or inhibiting brain activity related to addiction.See study design
What are the potential side effects?
While rTMS is generally considered safe, potential side effects include discomfort at the treatment site, headache, lightheadedness, tingling sensations during scalp application or muscle contractions under the treatment coil.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pre-rtms), end of rtms (end of treatment week 4 of rtms), an average of 8 weeks from baseline assessment to end of rtms, follow-up (4-weeks post-rtms) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of study completion as assessed by completion rates
Tolerability of Intervention as assessed by adverse event reporting
Secondary outcome measures
Anxiety symptoms
Cannabis Craving
Cannabis Use
+7 more

Trial Design

2Treatment groups
Active Control
Group I: High-Frequency (HF)Active Control1 Intervention
10 Hz rTMS
Group II: Low-Frequency (LF)Active Control1 Intervention
1 Hz rTMS

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthLead Sponsor
358 Previous Clinical Trials
81,209 Total Patients Enrolled
Brain & Behavior Research FoundationOTHER
61 Previous Clinical Trials
2,756 Total Patients Enrolled

Media Library

Repetitive Transcranial Magnetic Stimulation (Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05859347 — N/A
Cannabis Use Disorder Research Study Groups: High-Frequency (HF), Low-Frequency (LF)
Cannabis Use Disorder Clinical Trial 2023: Repetitive Transcranial Magnetic Stimulation Highlights & Side Effects. Trial Name: NCT05859347 — N/A
Repetitive Transcranial Magnetic Stimulation (Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05859347 — N/A
~21 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top